ONCY News and Press, Oncolytics Biotech Inc. From 12/02/20

FN Media Group Presents USA News Group News Commentary Vancouver, BC – December 2, 2020 – USA News Group – Triple-negative Breast Cancer (TNBC) is a highly aggressive subtype that accounts for 15-20% of breast cancer cases and 25% of all breast...

Gainers: Sundial Growers (SNDL) +35%, FSD Pharma (HUGE) +32%, Apollo Endosurgery (APEN) +26%, G1 Therapeutics (GTHX) +23%, Oncolytics Biotech (ONCY) +17%.Losers: SCWorx (WORX) -14%, 9 Meters Biopharma (NMTR) -14%, AnPac Bio-Medical Science (ANPC)&#...

Thousands of years ago, ancient Aztecs may have held the key to the next biotech breakthrough . During ceremonial rituals, they used a special compound they called “the flesh of the gods”... And today, researchers are discovering that this same compound could trans...

Oncolytics Biotech® Announces Positive Clinical Results Against Glioblastoma Multiforme at the 2020 Society of Neuro-Oncology Annual Meeting Pelareorep delivers efficacy, safety, and tolerability in difficult-to-treat GBM Canada NewsWire SAN DIEGO, Calif. and CALGAR...

Oncolytics Biotech® to Present AWARE-1 Data and Provide Updates on Phase 2 BRACELET-1 and IRENE Trials at the 2020 San Antonio Breast Cancer Symposium Canada NewsWire SAN DIEGO, Calif. and CALGARY, Alberta, Nov. 17, 2020 SAN DIEGO, Calif. and CALGARY, Albe...

Oncolytics Biotech Inc. (ONCY) Q3 2020 Earnings Conference Call November 11, 2020 5:00 PM ET Company Participants Jon Patton - Director of Investor Relations and Communication Matt Coffey - President and Chief Executive Officer Andrew de Guttadauro - Global Head of Business Development Kirk L...

Oncolytics Biotech® Reports 2020 Third Quarter Development Highlights and Financial Results Recently announced AWARE-1 data further support the potential of pelareorep to induce a durable anti-tumor immune memory effect and improve outcomes in breast cancer Initiated do...

Palm Beach, FL –November 9, 2020 – Much time and money has been allocated in the global breast cancer drug market, and multiple reports project continued growth in the sector. Early detection, increase in awareness, and incidence of breast cancer are some of the key trends sto...

Oncolytics Biotech® and SOLTI Present Clinical Breast Cancer Data Highlighting Pelareorep-Induced Anti-Tumor T Cell Responses at The Society for Immunotherapy of Cancer Annual Meeting Canada NewsWire SAN DIEGO, CA and CALGARY, AB, Nov. 9, 2020 - AWARE-1 data s...

Oncolytics Biotech® Announces Abstract Publication and Upcoming Oral Presentation at the 2020 Society of Neuro-Oncology Annual Meeting - Data from a phase 1b, investigator-sponsored study show that a pelareorep-based combination therapy is safe and well-tolerated in newly d...